Integrative Cancer Therapies最新文献

{"title":"Evaluating the Test-Retest Reliability and Measurement Error of a Sit-Stand-Power Test in Individuals Treated for Cancer.","authors":"Genevieve L Bottone, Kenneth S Anderson, Alexander M Brooks, Shana E Harrington, Bruce Nakfoor, Kylah E Jackson, Brett M Scott, Ciaran M Fairman","doi":"10.1177/15347354261442462","DOIUrl":"10.1177/15347354261442462","url":null,"abstract":"<p><strong>Introduction: </strong>Muscular strength and physical function are commonly assessed in exercise oncology trials, yet muscular power is often overlooked despite being an important determinant of morbidity and mortality. The sit-to-stand power (STSp) test offers a rapid, low-cost method to evaluate lower-body power. The purpose of this study was to assess the test-retest reliability, measurement error, and minimal detectable change (MDC) of the STSp test assessed using a linear power transducer in individuals treated for cancer.</p><p><strong>Methods: </strong>Adults with a history of cancer completed the STSp test on 2 occasions (2 -10 days apart), to evaluate test-retest reliability using intraclass correlation coefficients (ICC(3,1)). Standard error of measurement (SEM) and MDC were calculated.</p><p><strong>Results: </strong>One hundred and three individuals treated for cancer (88.3% female; mean age = 60.2 ± 10.4 years) completed the test-retest assessment. The sample was racially diverse, with 51% identifying as White and 41% as Black. Breast cancer was the most common diagnosis (68.9%). Disease stage was primary early stage, with 45.6% classified as stage I and 22.3% stage II. Participants had undergone surgery (95.2%), radiation (63.1%), and chemotherapy (60.2%). The STSp test demonstrated good reliability for peak power (ICC = 0.86; 95% CI: 0.80-0.91) and average power (ICC = 0.86; 95% CI: 0.79-0.90). The peak power SEM and MDC were 199.9 W and 554.10 W, respectively. The average power SEM and MDC were 179.05 W and 496.30 W, respectively.</p><p><strong>Conclusion: </strong>The STSp test demonstrated good test-retest reliability for assessing lower-body muscular power in individuals treated for cancer. Given its low cost and feasibility, the STSp test may be useful for clinicians seeking to monitor changes in lower extremity power in oncological settings. However, the relatively large SEM and MDC values indicate substantial within-subject variability, underscoring the need for further protocol standardization.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov, NCT06039488.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261442462"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13121485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amazonian and Related Phytotherapy for Cancer-Related Fatigue: A Narrative Review of Clinical and Mechanistic Evidence.","authors":"Auro Del Giglio","doi":"10.1177/15347354261498229","DOIUrl":"https://doi.org/10.1177/15347354261498229","url":null,"abstract":"<p><p>Cancer-related fatigue (CRF) is one of the most debilitating symptoms experienced by cancer patients, with a multifactorial etiology involving inflammatory, metabolic, neuroendocrine, and psychological mechanisms. As pharmacological treatments for CRF remain limited and often ineffective, interest has grown in complementary approaches, including the use of Amazonian and related plant extracts. Plant extracts contain various bioactive compounds with multiple pharmacological activities that may be beneficial in addressing complex multifactorial symptoms such as CRF.</p><p><strong>Purpose: </strong>This narrative review evaluates the clinical and mechanistic evidence surrounding the use of two Amazonian plants-Paullinia cupana (guaraná) and Uncaria tomentosa (cat's claw)-and one Asian-origin plant naturalized in the Brazilian Amazon-Zingiber zerumbet (bitter ginger)-for the management of CRF.</p><p><strong>Major findings: </strong>We discuss their phytochemical profiles, proposed biological effects, and the findings of preliminary clinical studies. A notable limitation of the available evidence is that ten of the twelve clinical studies reviewed originate from the author's home institution (Faculdade de Medicina da Fundação ABC), raising important questions about generalizability that future multicenter trials should address. Although preliminary results suggest potential benefits in CRF symptom control and quality of life, methodological limitations and heterogeneity across studies warrant caution. Importantly, guaraná was associated with worsening outcomes in patients with head and neck cancer undergoing concurrent chemoradiotherapy, underscoring that treatment-type-specific safety must be carefully considered before clinical use.</p><p><strong>Conclusions: </strong>Further well-powered, placebo-controlled, multicenter trials are essential to validate these findings and support clinical integration.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261498229"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149193197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Glutathione Metabolites and Reactive Oxygen Species from Baseline to Post-Treatment in Breast Cancer Survivors with Psychoneurological Symptoms Receiving Acupuncture.","authors":"Hongjin Li, Shuang Gao, Judith M Schlaeger, Hannah Choi, Yinglin Xia, Jun Sun, Ardith Z Doorenbos","doi":"10.1177/15347354251411913","DOIUrl":"10.1177/15347354251411913","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate acupuncture-induced changes in targeted glutathione metabolites in breast cancer survivors with psychoneurological symptoms (PNS) and to examine associations between these metabolic changes and PNS improvements.</p><p><strong>Methods: </strong>This exploratory phase II single-arm study (N = 42) evaluated a 10-session, 5-week acupuncture intervention for PNS management in breast cancer survivors. Targeted glutathione metabolites (ie, reduced glutathione (GSH), oxidized glutathione (GSSG), cysteine-glutathione disulfide (CySSG), GSH/GSSG ratio) and reactive oxygen species (ROS) were measured pre- and post-treatment. Paired <i>t</i>-test and Wilcoxon signed-rank tests assessed changes in these biomarkers. The PNS were assessed using Patient-Reported Outcomes Measurement Information System (PROMIS)-29.</p><p><strong>Results: </strong>ROS levels significantly increased post-treatment (2.34 ± 1.02-2.83 ± 1.23 μmol/L, <i>P</i> = .017), while GSSG levels significantly decreased (0.19 ± 0.23-0.12 ± 0.23 µmol/L, <i>P</i> < .001). GSH/GSSG ratio significantly increased (2.73 ± 1.21-5.38 ± 1.99, <i>P</i> < .001), indicating a shift toward reduced oxidative stress. GSH and CySSG levels showed non-significant increases after acupuncture (GSH: 0.38 ± 0.14-0.42 ± 0.16 µmol/L, <i>P</i> = .07; CySSG: 0.00503 ± 0.00082-0.00532 ± 0.00076 µmol/L, <i>P</i> = .06). No significant correlations were found between changes in GSH metabolites and PNS composite scores or individual symptom scores.</p><p><strong>Conclusion: </strong>Acupuncture may modulate GSH metabolism, improve redox balance, and enhance antioxidant capacity in breast cancer survivors with PNS. However, these biochemical changes were not correlated with PNS improvement, suggesting that alternative pathways may mediate acupuncture's therapeutic effects.Trial registry information:The study was registered in ClinicalTrials.gov (Identifier: NCT05417451).</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251411913"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12905098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146179410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Effect of Gemcitabine Combined With Angelica Polysaccharide on Triple Negative Breast Cancer in Mice.","authors":"Fan Lei, Weiling Xiao, Yating Shu, Na Li, Yanqing Liu, Zhentao Guo, Meiyu Peng","doi":"10.1177/15347354251414897","DOIUrl":"10.1177/15347354251414897","url":null,"abstract":"<p><strong>Objective: </strong>This study delves into the therapeutic effects of combining GEM and Angelica polysaccharide (APS) on triple-negative breast cancer.</p><p><strong>Methods: </strong>In vitro, proliferation, apoptosis of 4T-1 cells and MDSC were detected by flow cytometry. Migration of 4T-1 cell was detected by scratch healing experiment after treatment by GEM (0, 2.5, 5 μM), APS (160,320 mg/ml), or GEM + APS (2.5 μM + 160 mg/ml, 5 μM + 320 mg/ml). In vivo, 4T-1 cells were injected into the mammary fat pad under the mammary gland of BALB/c mice to establish an orthotopic breast cancer tumor model. They were randomly divided into control group (0.9% normal saline + ultrapure water), GEM group (0.9% normal saline preparation, 100 mg/kg, intraperitoneal injection twice a week), APS group (ultrapure water preparation, 200 mg/kg, intraperitoneal injection once a day), GEM + APS group (GEM 100 mg/kg, intraperitoneal injection twice a week and APS 200 mg/kg, intraperitoneal injection once a day) for 3 weeks. The proportion of immune cells in the spleen and tumor microenvironment were detected by flow cytometry, immunofluorescence and Mindray hematology analyzer. The tumor volume and weight, spleen index were recorded.</p><p><strong>Results: </strong>The in vitro experimental results revealed that GEM effectively inhibited the proliferation and migration of 4T-1 cells and induced apoptosis in both 4T-1 cells and MDSCs. In contrast, APS had no impact on 4T-1 cells or MDSCs. The in vivo experimental findings indicated that compared with the single-drug treatment groups, the combination treatment of GEM + APS more effectively regulated the proportion of peripheral and local anti-tumor MDSCs and T cells, and more significantly curbed the progression of breast cancer in mice.</p><p><strong>Conclusion: </strong>APS can exert a synergistic effect through immune regulation to enhance the therapeutic efficacy of GEM on triple-negative breast cancer. It aims to offer novel insights for the clinical application of combining GEM with immunotherapy for patients with triple negative breast cancer.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251414897"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12909758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146206989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Mechanism Underlying Inhibition of Colorectal Cancer Invasion by Quxie Capsule Through CRK-RAC Signaling Pathway Regulation.","authors":"Jiang-Yu Bian, Yu-Xing Sun, Lin-Feng Wang, Yu-Fei Yang, Tong Zhang","doi":"10.1177/15347354261487221","DOIUrl":"10.1177/15347354261487221","url":null,"abstract":"<p><p>BackgroundOur previous studies showed that Quxie capsule (QX) remarkably prolongs the survival of patients with advanced colorectal cancer (CRC) and downregulates CT10 regulator of kinase (CRK) protein expression in responders. However, the underlying mechanism through which QX inhibits CRC invasion remains unclear.ObjectiveTo elucidate the mechanism through which QX suppresses CRC invasion.MethodsThe IC₅₀ values of QX and 5-fluorouracil (5-FU) were determined by CCK-8 assay to establish drug intervention concentrations. Flow cytometry, Transwell assays, and hematoxylin-eosin (HE) staining were used to evaluate the effects of QX and 5-FU combination on the proliferation, apoptosis, cell cycle, migration, invasion, and tube formation ability of CRC cells. Modulation of the CRK-RAC signaling pathway was analyzed by qRT-PCR and western blotting assay. For <i>in vivo</i> validation assay, tumor-bearing nude mouse models were utilized to measure tumor volume, and HE staining, immunohistochemical assay were conducted to assess tumor proliferation and apoptosis. A sh-CRKL knockdown stable cell line was established to investigate the role of CRKL in CRC invasion through simultaneous <i>in vitro</i> and <i>in vivo</i> experiments.ResultsProteomics analysis identified Crk-like protein (CRKL) as a differentially expressed protein in CRC. In vitro experiments demonstrated that the combined treatment of QX (0.589 mg/mL, 0.597 mg/mL) with 5-FU (4.036 μg/mL, 6.417 μg/mL) could enhance the inhibition of the proliferation of CRC cells (HCT116 and SW620) and induced apoptosis (P < 0.05), while significantly downregulating the CRKL-RAC signaling pathway activity. Knocking down the CRKL gene further confirmed that CRKL deficiency inhibits cancer cell invasion; in the CRKL-deficient model, the combination therapy of QX and 5-FU further enhanced the inhibitory effect on tumor progression (P < 0.05). In vivo experiments also validated the efficacy of this combination therapy: compared with the monotherapy group, the combination of QX and 5-FU significantly inhibited tumor growth in tumor-bearing mice (P < 0.05) and was accompanied by downregulation of key proteins in the CRKL-RAC signaling pathway (P < 0.05).ConclusionQX inhibits CRC invasion by downregulating CRKL protein expression and modulating the CRK-RAC signaling pathway; this finding provides a mechanistic basis for validating the clinical efficacy of QX.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261487221"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148919644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Catalpol Reactivates IL-7R-STAT5 Signaling and Reverses Radiation-Induced T Helper 1 Cells Deficiency to Limit Melanoma Metastasis to Lung.","authors":"Shan Zhang, Yue Zhang, Mingyan Ma, Junjie Huang, Rongrui Tang, Wenlian Hao","doi":"10.1177/15347354261453338","DOIUrl":"10.1177/15347354261453338","url":null,"abstract":"<p><strong>Background: </strong>Radiation-induced quantitative deficiency of T helper 1 (Th1) cells accelerates lung tumor development. Here, we evaluated IL-7R-STAT5 signaling in Th1 recovery after irradiation and examined how catalpol contributes to Th1 reconstitution by targeting this signaling axis in mice.</p><p><strong>Methods: </strong>The recovery characteristics of irradiated Th1 cells, compared with other IFN-γ-producing (IFN-γ⁺) cells, were analyzed in local radiotherapy (LRT) mice challenged with lung melanoma and single low-dose total body irradiation (SLTBI) mice without tumor. IL-7R-STAT5 signaling of Th1 from LRT mice, treated with or without catalpol, was evaluated using flow cytometry and RT-qPCR. The role of IL-7-IL-7R-STAT5 signaling in irradiated Th1 cells was further confirmed in irradiated EL4 cells following administration of IL-7 or catalpol.</p><p><strong>Results: </strong>Th1 subsets showed delayed recovery in both LRT and SLTBI mice compared with other IFN-γ⁺ cells, and irradiated Th1 cells exhibited decreased activation of IL-7R-STAT5 signaling. Quantitative reduction of Th1 cells increased lung metastasis of B16 melanoma in irradiated mice. Irradiated EL4 cells also displayed decreased IL-7R-STAT5 signaling and reduced IFN-γ production in vitro. Treatment with catalpol could restore IL-7R-STAT5 signaling and promote Th1 recovery following irradiation both in vivo and in vitro. Catalpol-mediated restoration of IL-7R-STAT5 signaling in Th1 provided superior protection against B16 melanoma metastasis to the lung.</p><p><strong>Conclusions: </strong>IL-7R-STAT5 signaling is required for Th1 recovery after irradiation. Catalpol effectively promotes Th1 cell reconstitution and decreases B16 melanoma metastasis to the lung by enhancing IL-7R-STAT5 signaling. These findings provide new strategies for improving radiotherapy and immunotherapy outcomes in cancer.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261453338"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13237464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Fasting as a Novel Approach to Mitigate Musculoskeletal Symptoms in Breast Cancer Patients undergoing Aromatase Inhibitor Therapy: A Feasibility Study Protocol.","authors":"Henriette Meyer, Daniela A Koppold, Osaid Shaker, Laura Eden, Lisa Schiffmann, Stefan Konigorski, Holger Cramer, Kyung-Eun Anna Choi, Hermann Einsele, Marcela Winkler, Claudia Löffler","doi":"10.1177/15347354261426272","DOIUrl":"10.1177/15347354261426272","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) or aromatase inhibitor-induced arthralgia (AIA), common side effects of long-term adjuvant endocrine therapy for breast cancer patients, can significantly affect quality of life. Preliminary clinical evidence suggests that fasting may alleviate these symptoms, as demonstrated in conditions such as rheumatoid arthritis and fibromyalgia. This study aims to evaluate the feasibility and acceptability of prolonged therapeutic fasting program, including structured behavioral and educational support, in patients with AIMSS/AIA and explore the applicability of validated measurement tools for assessing symptom burden in preparation for a confirmatory bicentric trial.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This is a bicentric, single-arm, prospective pilot study. We will enroll 54 participants undergoing endocrine therapy with aromatase inhibitors who suffer from AIMSS/AIA. All participants will receive a 7-day online- prolonged therapeutic fasting intervention (max. 350 kcal/day), consisting of vegetable juices and broths under medical supervision. The primary outcome is the feasibility of prolonged therapeutic fasting during aromatase inhibitor therapy assessed through participant adherence to the fasting protocol and completion rate. As a secondary endpoint, we will assess the feasibility of using validated measurement instruments to collect data on symptoms, quality of life, mindfulness, stress, and sleep quality in preparation for a confirmatory trial. The following well established tools will be used: Numeric Rating Scale (NRS), Visual Analog Scale (VAS), Brief Pain Inventory (BPI), Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire-Disability Index (HAQ-DI), WHO-5 Well-Being Index (WHO-5), Mindful Attention Awareness Scale (MAAS), Brief Fatigue Inventory (BFI) and Pittsburgh Sleep Quality Index (PSQI). Specifically, we aim to explore their applicability by evaluating completion rates, participant acceptability, and data completeness within this patient population. Exploratory parameters, including changes in dietary habits, anthropometric data, and cancer-related fatigue will be tracked to contextualize the feasibility findings and inform outcome selection for a future confirmatory trial. An accompanying N-of-1 trial using a mobile application (StudyU) and qualitative interviews will give more insight into individual and subjective changes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;If the intervention proves feasible and well accepted, these findings will support the development of a confirmatory trial designed to investigate the potential clinical benefits and underlying mechanisms of fasting in AIMSS/AIA. Long-term studies incorporating biomarkers and microbiota analysis could further explore the mechanisms underlying symptom improvement and guide personalized treatment strategies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Trial registration: &lt;/strong&gt;ClinicalTrials.gov.NCT","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261426272"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12979920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147432686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Protective and Anti-fibrotic Properties of Genistein in a Rat Model of Cirrhosis and Liver Cancer.","authors":"Maneerat Chayanupatkul, Kanjana Somanawat, Natcha Wanpiyarat, Duangporn Werawatganon","doi":"10.1177/15347354261492310","DOIUrl":"https://doi.org/10.1177/15347354261492310","url":null,"abstract":"<p><p>IntroductionHepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, particularly in patients with cirrhosis. Genistein (GEN), a tyrosine kinase inhibitor with a favorable safety profile, has potential as a chemoprotective agent in high-risk populations. This study evaluated the effects of GEN in a rat model of diethylnitrosamine (DEN)-induced cirrhosis and HCC.MethodsThirty-three male Sprague Dawley rats were randomized into three groups (n=11/group): Control, HCC, and HCC+GEN. HCC was induced by weekly intraperitoneal DEN injections (70 mg/kg) for 16 weeks. From weeks 8-16, the GEN group received oral genistein (50 mg/kg/day), while other groups received vehicle. Liver tissues were examined histopathologically and immunohistochemically for HCC, caspase-9, ERK-1, α-SMA, and MMP-2. Tumor burden was calculated to reflect tumor size and number. Serum AFP, p53, and biochemical parameters were analyzed.ResultsTumor burden was significantly increased in the HCC group compared with controls and was significantly reduced by GEN treatment (p=0.002). Elevated serum AFP and p53 levels in the HCC group were significantly decreased with GEN. Although cirrhosis developed in both HCC groups, collagen deposition was significantly lower in the GEN-treated rats. GEN treatment was associated with reduced expression of ERK-1, α-SMA, and MMP-2, and increased caspase-9 expression, indicating anti-proliferative, anti-fibrotic, and pro-apoptotic effects.ConclusionsGenistein reduced tumor burden, serum tumor markers, and liver fibrosis in a rat model of HCC, supporting its potential as a chemoprotective agent in cirrhotic livers. Further dose-optimization and clinical studies are warranted.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261492310"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Associations for Use of Complementary and Alternative Medicine (CAM) Among Paediatric Cancer Patients in Norway: A Cross-Sectional Survey.","authors":"Agnete E Kristoffersen, Trine Stub, Eran Ben-Arye, Miek C Jong, Dana C Mora","doi":"10.1177/15347354261498232","DOIUrl":"https://doi.org/10.1177/15347354261498232","url":null,"abstract":"<p><p>In Norway, 7,400 individuals diagnosed with childhood cancer before the age of 18 are alive today, facing lasting burdens from the disease and its treatment. This study investigates the prevalence of complementary and alternative medicine (CAM) use among children with cancer in Norway, based on parental reports. It also examines the types of CAM modalities used, their perceived effects, safety, and associated demographic and cancer-related factors. An online cross-sectional survey was conducted in 2021 in collaboration with the Norwegian Children's Cancer Society. The study utilised a modified version of the International Questionnaire to Measure Use of Complementary and Alternative Medicine (I-CAM-Q), adapted for children with cancer. Data were collected from 95 mothers and 22 fathers, covering 117 children, using convenience sampling with a response rate of 17%. Nearly half (47%, n=55) of parents reported that their children used CAM during or after cancer treatment. Modalities included vitamin D supplementation (19%, n=22), music therapy (18%, n=21), art therapy (16%, n=19), psychotherapy (9%, n=10), and massage or aromatherapy (8%, n=9). Although 82% (n = 45) of parents of children using CAM reported benefits, 7% (n = 4) reported adverse effects associated with these modalities. CAM use was primarily motivated by the burden of adverse and late effects of cancer treatment, such as fatigue (p=0.004), worry or unrest (p=0.036), and memory or concentration difficulties (p<0.001). The findings suggest that non-verbal and creative forms of support, such as massage, music therapy, and art therapy, were highly valued in this national sample. Further research is needed to better understand the unmet needs and expectations of both parents and children and to improve the quality of life for children with cancer and their families.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261498232"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149244062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative Chinese Herbal Medicine as Adjuvant Management for Triple-Negative Breast Cancer: A Multi-Institutional Real-World Study With Mechanism Exploration.","authors":"Hsiang-I Hou, Hsu-Huan Chou, Chao-Wei Lee, Hsing-Yu Chen","doi":"10.1177/15347354261451843","DOIUrl":"10.1177/15347354261451843","url":null,"abstract":"<p><strong>Background: </strong>Triple-negative breast cancer (TNBC) is a major cause of mortality worldwide. Chinese herbal medicine (CHM) is often used as adjunctive therapy, but its long-term impact on TNBC remains unclear.</p><p><strong>Materials and methods: </strong>This study analyzed a multi-institutional cohort from the Chang Gung Research Database, investigating long-term outcomes of integrative CHM use in TNBC patients newly diagnosed between January 1, 2011, and December 31, 2021. Patients were followed for up to 10 years or until death. Overall survival rate (OS) and disease-specific survival rates were assessed using Kaplan-Meier estimation with overlap weighting and landmark analysis to reduce bias. Core CHMs were identified through network pharmacology analysis on prescriptions made for TNBC patients.</p><p><strong>Results: </strong>The analysis included 2174 TNBC patients, with 464 using CHM. CHM use was associated with a significantly higher 10-year OS compared to non-users (77.7% vs 70.2%, <i>P</i> = .007). In stages 1 to 3, the OS among CHM users was 6.6% higher (80.7% vs 74.1%, <i>P</i> = .018). After adjusting for demographic factors, CHM use reduced the risk of all-cause mortality (adjusted hazard ratio [aHR]: 0.71, <i>P</i> = .044). Lower disease-specific survival rates were observed among CHM users. Core CHMs, such as <i>Hedyotis diffusa Willd.</i>, may have potential anti-cancer effects, while combinations like Jia-Wei-Xiao-Yao-San, <i>Scutellaria barbata</i> D. Don. and Suan-Zao-Ren-Tang may have a complementary role to standard treatments for TNBC.</p><p><strong>Conclusion: </strong>Use of CHM may improve 10-year OS in TNBC patients, and core CHMs provided crucial references for further studies.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261451843"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13237460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}